Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Rouzier R, et al. Among authors: morandi p. Clin Cancer Res. 2005 Aug 15;11(16):5678-85. doi: 10.1158/1078-0432.CCR-04-2421. Clin Cancer Res. 2005. PMID: 16115903
Gene expression profiling of primary breast cancer.
Rouzier R, Wagner P, Morandi P, Pusztai L. Rouzier R, et al. Among authors: morandi p. Curr Oncol Rep. 2005 Jan;7(1):38-44. doi: 10.1007/s11912-005-0024-y. Curr Oncol Rep. 2005. PMID: 15610685 Review.
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Gonzalez-Angulo AM, et al. Among authors: morandi p. J Clin Oncol. 2005 Oct 1;23(28):7098-104. doi: 10.1200/JCO.2005.11.124. J Clin Oncol. 2005. PMID: 16192593
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Cristofanilli M, et al. Among authors: morandi p. Ann Oncol. 2008 Oct;19(10):1713-9. doi: 10.1093/annonc/mdn352. Epub 2008 May 29. Ann Oncol. 2008. PMID: 18515258 Free PMC article. Clinical Trial.
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Goldstein LJ, Mansutti M, Levy C, Chang JC, Henry S, Fernandez-Perez I, Prausovà J, Staroslawska E, Viale G, Butler B, McCanna S, Ruffini PA, Wicha MS, Schott AF; fRida Trial Investigators. Goldstein LJ, et al. Breast Cancer Res Treat. 2021 Nov;190(2):265-275. doi: 10.1007/s10549-021-06367-5. Epub 2021 Sep 3. Breast Cancer Res Treat. 2021. PMID: 34476645 Free PMC article. Clinical Trial.
118 results